A group of researchers inhibited DNMT expression in vivo using Decitabine and observed reduced tumor growth in patient-derived xenograft models of prostate cancer, along with increased expression of the costimulatory/coinhibitory immunoregulatory protein B7 homolog 3 (B7-H3), which is an emerging therapeutic target for cancer [242]. The gene discussed is DNMT1; the disease is prostate cancer.